Vaccine maker Novavax initiated a clinical study of H1N1 swine flew vaccine in mexico. this study will evaluate safety, immunogenicity and efficacy of the virus like particle vaccine, says Novavax in a statement.
Avimex, which is funding the trial, is expected to market the vaccine in Mexico if approved. GE health care will support the study by providing its single-use bio-processing technologies for vaccine production.